Howe & Rusling’s Iterum Therapeutics ITRM Stock Holding History

Howe & Rusling’s Portfolio ITRM Stock Details ITRM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-33	Closed	–	–	671
2022 Q3	$0	Hold	33	–	–	﹤0.01%	1126
2022 Q2	$0	Hold	33	–	–	﹤0.01%	1114
2022 Q1	$0	Hold	33	–	–	﹤0.01%	1038
2021 Q4	$0	Buy	+33	New	+$255	﹤0.01%	1031

Other funds holding ITRM

NLVP

New Leaf Venture Partners New York $43M AUM 25.55% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return

Krilogy Financial St. Louis, Missouri $3.38B AUM 30.57% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

FWM

Focused Wealth Management Newburgh, New York $964M AUM 18.71% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Howe & Rusling's ITRM Position: Q4 2022 in Review

Howe & Rusling sold out of Iterum Therapeutics (ITRM) in Q4 2022, closing a stake of 33 shares.

Howe & Rusling first reported a position in ITRM in Q4 2021 and held it in 4 quarters. The position peaked at $0 in Q3 2022. 23 funds tracked by Wall St. Rank hold ITRM as of Q4 2022.

Howe & Rusling reported no remaining Iterum Therapeutics position as of Q4 2022 after selling out during the quarter.
Howe & Rusling sold 33 Iterum Therapeutics shares in Q4 2022.
Howe & Rusling first reported a position in Iterum Therapeutics in Q4 2021 and held it in 4 quarters.
Howe & Rusling's Iterum Therapeutics position peaked at $0 in Q3 2022.
23 funds tracked by Wall St. Rank held Iterum Therapeutics as of Q4 2022.

Based on Howe & Rusling's 13F filing for Q4 2022, filed 15 Feb 2023.